

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A BREACH OF THE RELEVANT SECURITIES LAWS OF SUCH JURISDICTION.

THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT ITSELF CONSTITUTE A PROSPECTUS OR OFFERING MEMORANDUM OR AN OFFER FOR SALE OR SUBSCRIPTION IN RESPECT OF ANY SECURITIES IN THE COMPANY. THIS ANNOUNCEMENT DOES NOT CONSTITUTE OR CONTAIN ANY INVITATION, SOLICITATION, RECOMMENDATION, OFFER OR ADVICE TO ANY PERSON TO SUBSCRIBE FOR, OTHERWISE ACQUIRE OR DISPOSE OF ANY SECURITIES OF CRISM THERAPEUTICS CORPORATION IN ANY JURISDICTION IN WHICH ANY SUCH OFFER OR SOLICITATION WOULD BE UNLAWFUL.

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014, AS INCORPORATED INTO UK LAW BY THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("UK MAR"). UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN. ADDITION, MARKET SOUNDINGS (AS DEFINED IN UK MAR) WERE TAKEN IN RESPECT OF CERTAIN OF THE MATTERS CONTAINED WITHIN THIS ANNOUNCEMENT, WITH THE RESULT THAT CERTAIN PERSONS BECAME AWARE OF INSIDE INFORMATION (AS DEFINED UNDER UK MAR). UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THOSE PERSONS THAT RECEIVED INSIDE INFORMATION IN A MARKET SOUNDING ARE NO LONGER IN POSSESSION OF SUCH INSIDE INFORMATION, WHICH IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

30 June 2025



**CRISM Therapeutics Corporation**

("CRISM", "CRISM Therapeutics" or the "Company")

**Placing to raise approximately £800,000 (before expenses)**

CRISM Therapeutics Corporation (AIM: CRTX) the innovative UK drug delivery company focused on the localised delivery of chemotherapy drugs, is pleased to announce that it has successfully raised £800,000 (before expenses) by way of a placing of 6,666,668 new ordinary shares of no par value each in the Company ("Placing Shares") at a price of 12 pence per share (the "Issue Price") (the "Placing"). The Placing Shares each have an attaching grant of warrants ("Warrants") on a one for two basis, exercisable at a price of 24 pence per share, and expiring 24 months after the date of the admission to trading on AIM of the Placing Shares.

The Placing was undertaken by the Company's broker, SP Angel Corporate Finance LLP.

The Company values its retail shareholder base and believes that it is appropriate to provide existing retail shareholders the opportunity to purchase shares at the Issue Price. The Company intends to carry out a separate retail offer to raise further gross proceeds of up to £100,000 via the BookBuild Platform (the "Retail Offer"). A further announcement will be made shortly regarding the Retail Offer and its terms.

**Highlights of the Placing:**

- Completion of Placing raising £800,000 (before expenses) through the issue of 6,666,668 Placing Shares at 12 pence per share
- The Company will use the net proceeds of the Placing for:
  - o The GMP manufacture, sterilization, batch qualification, packaging and distribution of a clinical batch of ChemoSeed for evaluation of safety and efficacy in glioblastoma patients in a Phase 2 registration grade clinical trial
  - o Clinical trial set up costs, including first patients dosed in early 2026
- CRISM CEO, Andrew Webb, and Non-Executive Director, Gerry Beaney, both participated in the Placing
- A separate retail offer to existing holders will be launched shortly

**CRISM CEO, Andrew Webb, said:** "The strong support from investors in this fundraising reflects the positive progress we have delivered since joining AIM last year. We are now at a very exciting stage in the development of the Company as we move closer to the start of our Phase 2 trial in glioblastoma using our novel drug delivery platform, ChemoSeed. We thank investors for their support and look forward to the launch of the retail offer, which will give existing shareholders an opportunity to participate in this funding round. With this funding we now have the opportunity to accelerate the approval and commercialisation of a new, much needed treatment for this devastating disease."

**Rationale for the Placing**

The Placing will enable the Company to continue to progress the development of ChemoSeed. Specifically, the Placing proceeds will fund CRISM for GMP manufacture of a clinical trial batch of ChemoSeed, through the MHRA's Clinical Trial Authorisation approval process and to first patients dosed in CRISM's registration grade Phase 2 clinical trial in early 2026.

The Company's Clinical Trial Authorisation application for regulatory approval to conduct its Phase 2 trial is expected to

be submitted later today, and a further announcement will be made following the submission.

#### Directors' Participation and Related Party Transactions

Certain Directors of the Company have participated in the Placing, details of which are in the table below:

Director	Number of Placing Shares subscribed for	Number of ordinary shares held immediately following Admission	% interest in ordinary shares immediately following Admission
Andrew Webb	291,667	6,380,523	16.22%
Gerry Beaney	112,500	157,682	0.40%

The participation of Andrew Webb and Gerry Beaney in the Placing (including the issue of the Warrants referred to below) constitutes related party transactions for the purposes of Rule 13 of the AIM Rules for Companies. The Directors independent of the Placing, being Chris McConville and Nermeen Varawalla, consider, having consulted with SP Angel Corporate Finance LLP, the Company's Nominated Adviser, that the Directors' participation in the Placing is fair and reasonable in so far as CRISM's shareholders are concerned.

#### Warrants

The Company will issue participants of the Placing with one Warrant for every two Placing Shares. As a result, 3,333,330 Warrants will be issued to the placees. Each Warrant will provide the holder with the right to one new ordinary share on its exercise. The Warrants will be exercisable at a price of 24 pence for period of 24 months from the date of admission of the Placing Shares.

Directors Andrew Webb and Gerry Beaney have been issued with 145,833 and 56,250 Warrants respectively, as a result of their participation in the Placing.

#### Admission and Total Voting Rights

Application has been made to the London Stock Exchange for admission of the Placing Shares (**Admission**). It is expected that Admission will become effective and that trading will commence in the Placing Shares at 8.00 a.m. on or around 3 July 2025, or such later date as may be agreed between the Company and SP Angel. The Placing Shares will rank *pari passu* with the Company's existing ordinary shares.

Following the issue of the Placing Shares, the total issued share capital of the Company will consist of 39,344,980 ordinary shares. The Company does not hold any ordinary shares in treasury. Therefore, the total number of voting rights in the Company is 39,344,980 and this figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

-Ends-

#### Enquiries:

**Company**  
**CRISM Therapeutics Corporation**  
 Andrew Webb, CEO  
 Chris McConville, CSO  
 via Burson Buchanan

**Nomad and Broker**  
**S.P. Angel Corporate Finance LLP**  
 Richard Morrison  
 Adam Cowl  
 +44 (0) 20 3470 0470

**Financial PR**  
**Burson Buchanan**  
 Mark Court / Jamie Hooper  
 CRISM@buchanancomms.co.uk  
 +44 (0) 20 7466 5000

#### About CRISM Therapeutics Corporation

CRISM Therapeutics Corporation has developed an innovative drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs.

ChemoSeed, CRISM's lead product, can be implanted directly into the tumour or the resection margin following the removal of a tumour. This directs that therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour tissue or cover the entire resection margin. In the case of treating high-grade glioma, ChemoSeeds can be implanted during surgery thereby bypassing the blood brain barrier, which prevents other treatments from being able to reach the tumour and be effective.

For more information please visit: <https://www.crismmtherapeutics.com/>

#### Dealings by Persons Discharging Managerial Responsibilities

1	Details of the person discharging managerial responsibilities / person closely associated	
a)	Name	1) Andrew Webb 2) Gerald Beaney
2	Reason for the notification	
a)	Position/status	1) Chief Executive Officer 2) Non-Executive Director
b)	Initial notification /Amendment	Initial Notification

3	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>										
a)	Name	CRISM Therapeutics Corporation									
b)	LEI	213800XFW6MKVCHHPW88									
4	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>										
a)	Description of the financial instrument, type of instrument  Identification code	Ordinary shares with no par value  ISIN: VGG042401262									
b)	Nature of the transaction	Purchase of shares									
c)	Price(s) and volume(s)	<table border="1" data-bbox="480 824 995 904"> <thead> <tr> <th>Director/PDMR</th><th>Price</th><th>Volume</th></tr> </thead> <tbody> <tr> <td>Andrew Webb</td><td>12p</td><td>291,667</td></tr> <tr> <td>Gerald Beaney</td><td>12p</td><td>112,500</td></tr> </tbody> </table>	Director/PDMR	Price	Volume	Andrew Webb	12p	291,667	Gerald Beaney	12p	112,500
Director/PDMR	Price	Volume									
Andrew Webb	12p	291,667									
Gerald Beaney	12p	112,500									
d)	Aggregated information  - Aggregated volume  - Price	N/A  N/A									
e)	Date of the transaction	30 June 2025									
f)	Place of the transaction	Outside a trading venue									

1	<b>Details of the person discharging managerial responsibilities / person closely associated</b>	
a)	Name	1) Andrew Webb 2) Gerald Beaney
2	<b>Reason for the notification</b>	
a)	Position/status	1) Chief Executive Officer 2) Non-Executive Director
b)	Initial notification /Amendment	Initial Notification
3	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>	
a)	Name	CRISM Therapeutics Corporation
b)	LEI	213800XFW6MKVCHHPW88
4	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>	

a)	Description of the financial instrument, type of instrument  Identification code	Ordinary shares with no par value  ISIN: VGG042401262									
b)	Nature of the transaction	Issue of warrants									
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Director/PDMR</th><th>Price</th><th>Volume</th></tr> </thead> <tbody> <tr> <td>Andrew Webb</td><td>24p</td><td>145,833</td></tr> <tr> <td>Gerald Beaney</td><td>24p</td><td>56,250</td></tr> </tbody> </table>	Director/PDMR	Price	Volume	Andrew Webb	24p	145,833	Gerald Beaney	24p	56,250
Director/PDMR	Price	Volume									
Andrew Webb	24p	145,833									
Gerald Beaney	24p	56,250									
d)	Aggregated information  - Aggregated volume  - Price	N/A  N/A									
e)	Date of the transaction	30 June 2025									
f)	Place of the transaction	Outside a trading venue									

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@seg.com](mailto:rns@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

IOEBKLLLEQLBBBZ